» Articles » PMID: 16418065

Characterization of the Enzymes Involved in the in Vitro Metabolism of Amrubicin Hydrochloride

Overview
Journal Xenobiotica
Publisher Informa Healthcare
Specialties Biochemistry
Toxicology
Date 2006 Jan 19
PMID 16418065
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The in vitro metabolism of amrubicin by rat and human liver microsomes and cytosol was examined. The main metabolic routes in both species were reductive deglycosylation and carbonyl group reduction in the side-chain. In vitro metabolism of amrubicinol by rat and human liver microsomes and cytosol was also examined and the main metabolic route of this active metabolite was reductive deglycosylation. Metabolism of amrubicin in human liver microsomes was inhibited by TlCl(3) and that in human liver cytosol was inhibited by dicumarol and quercetin. Generation of amrubicinol was inhibited only by quercetin. The results indicate that metabolism of amrubicin is mediated by NADPH-cytochrome P450 reductase, NADPH:quinone oxidoreductase and carbonyl reductase. In addition, generation of amrubicinol is mediated by carbonyl reductase. Metabolism of amrubicinol in human liver microsomes was inhibited by TlCl(3) and that in human liver cytosol was inhibited by dicumarol. The results indicate that metabolism of amrubicinol is mediated by NADPH-cytochrome P450 reductase and NADPH:quinone oxidoreductase. To investigate the influence of cisplatin on the metabolism of amrubicin and amrubicinol, human liver microsomes and cytosol were pre-incubated with cisplatin. This did not change the rates of amrubicin and amrubicinol metabolism in either human liver microsomes or cytosol.

Citing Articles

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.

Imai H, Nagai Y, Minemura H, Tsuda T, Yamada Y, Wasamoto S Invest New Drugs. 2022; 40(5):1066-1079.

PMID: 35749041 PMC: 9395483. DOI: 10.1007/s10637-022-01269-9.


Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma.

Kaira K, Imai H, Yamaguchi O, Mouri A, Kagamu H Cancers (Basel). 2021; 13(21).

PMID: 34771601 PMC: 8582353. DOI: 10.3390/cancers13215441.


Occurrence of Hematological Malignancy in Long-term Survivors With Advanced Thymic Cancer.

Kaira K, Naruse I, Shinomiya S, Kagamu H In Vivo. 2020; 34(3):1511-1513.

PMID: 32354955 PMC: 7279802. DOI: 10.21873/invivo.11938.


Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.

Sakurai R, Kaira K, Miura Y, Sunaga N, Saito R, Oyama T Thorac Cancer. 2020; 11(2):426-435.

PMID: 31901017 PMC: 6997014. DOI: 10.1111/1759-7714.13289.


A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.

Imai H, Sugiyama T, Tamura T, Minemura H, Kaira K, Kanazawa K Cancer Chemother Pharmacol. 2017; 80(3):615-622.

PMID: 28761968 PMC: 5573757. DOI: 10.1007/s00280-017-3403-9.